144 related articles for article (PubMed ID: 25710581)
1. The Diagnostic Utility of PAX8 for Neuroendocrine Tumors: An Immunohistochemical Reappraisal.
Liau JY; Tsai JH; Jeng YM; Kuo KT; Huang HY; Liang CW; Yang CY
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):57-63. PubMed ID: 25710581
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors.
Lorenzo PI; Jimenez Moreno CM; Delgado I; Cobo-Vuilleumier N; Meier R; Gomez-Izquierdo L; Berney T; Garcia-Carbonero R; Rojas A; Gauthier BR
Histochem Cell Biol; 2011 Nov; 136(5):595-607. PubMed ID: 21932072
[TBL] [Abstract][Full Text] [Related]
3. PAX8 mouse monoclonal antibody [BC12] recognizes a restricted epitope and is highly sensitive in renal cell and ovarian cancers but does not cross-react with b cells and tumors of pancreatic origin.
Tacha D; Qi W; Zhou D; Bremer R; Cheng L
Appl Immunohistochem Mol Morphol; 2013 Jan; 21(1):59-63. PubMed ID: 22595948
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors.
Lai JP; Mertens RB; Mirocha J; Koo J; Venturina M; Chung F; Mendez AB; Kahn M; Dhall D
Endocr Pathol; 2015 Mar; 26(1):54-62. PubMed ID: 25433656
[TBL] [Abstract][Full Text] [Related]
5. Value of PAX 8 immunostaining in tumor diagnosis: a review and update.
Ordóñez NG
Adv Anat Pathol; 2012 May; 19(3):140-51. PubMed ID: 22498579
[TBL] [Abstract][Full Text] [Related]
6. Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody.
Toriyama A; Mori T; Sekine S; Yoshida A; Hino O; Tsuta K
Histopathology; 2014 Oct; 65(4):465-72. PubMed ID: 24592933
[TBL] [Abstract][Full Text] [Related]
7. PAX8 is expressed in pancreatic well-differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine-needle aspiration biopsy specimens.
Haynes CM; Sangoi AR; Pai RK
Cancer Cytopathol; 2011 Jun; 119(3):193-201. PubMed ID: 21328566
[TBL] [Abstract][Full Text] [Related]
8. PAX-8 expression in primary and metastatic Merkel cell carcinoma: an immunohistochemical analysis.
Sangoi AR; Cassarino DS
Am J Dermatopathol; 2013 Jun; 35(4):448-51. PubMed ID: 23612030
[TBL] [Abstract][Full Text] [Related]
9. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma.
Sangoi AR; Ohgami RS; Pai RK; Beck AH; McKenney JK; Pai RK
Mod Pathol; 2011 Mar; 24(3):412-24. PubMed ID: 20890270
[TBL] [Abstract][Full Text] [Related]
10. The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin.
Koo J; Zhou X; Moschiano E; De Peralta-Venturina M; Mertens RB; Dhall D
Endocr Pathol; 2013 Dec; 24(4):184-90. PubMed ID: 24037217
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive analysis of PAX8 expression in human epithelial tumors.
Laury AR; Perets R; Piao H; Krane JF; Barletta JA; French C; Chirieac LR; Lis R; Loda M; Hornick JL; Drapkin R; Hirsch MS
Am J Surg Pathol; 2011 Jun; 35(6):816-26. PubMed ID: 21552115
[TBL] [Abstract][Full Text] [Related]
12. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors.
Zhao LH; Chen C; Mao CY; Xiao H; Fu P; Xiao HL; Wang G
Pathol Res Pract; 2019 Jul; 215(7):152448. PubMed ID: 31133441
[TBL] [Abstract][Full Text] [Related]
13. Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis.
Weissferdt A; Moran CA
Am J Surg Pathol; 2011 Sep; 35(9):1305-10. PubMed ID: 21836478
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PAX8 Expression in Breast Carcinoma Using MRQ50 and BC12 Monoclonal Antibodies.
Singh K; Hanley LC; Sung CJ; Quddus MR
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):558-561. PubMed ID: 31335489
[TBL] [Abstract][Full Text] [Related]
15. PAX8 is expressed in the majority of renal epithelial neoplasms: an immunohistochemical study of 223 cases using a mouse monoclonal antibody.
Hu Y; Hartmann A; Stoehr C; Zhang S; Wang M; Tacha D; Montironi R; Lopez-Beltran A; Cheng L
J Clin Pathol; 2012 Mar; 65(3):254-6. PubMed ID: 22135028
[TBL] [Abstract][Full Text] [Related]
16. PAX8 Expression in well-differentiated pancreatic endocrine tumors: correlation with clinicopathologic features and comparison with gastrointestinal and pulmonary carcinoid tumors.
Long KB; Srivastava A; Hirsch MS; Hornick JL
Am J Surg Pathol; 2010 May; 34(5):723-9. PubMed ID: 20414099
[TBL] [Abstract][Full Text] [Related]
17. PAX2 and PAX8 expression in primary and metastatic müllerian epithelial tumors: a comprehensive comparison.
Ozcan A; Liles N; Coffey D; Shen SS; Truong LD
Am J Surg Pathol; 2011 Dec; 35(12):1837-47. PubMed ID: 21989345
[TBL] [Abstract][Full Text] [Related]
18. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
19. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs].
Gurevich LE; Proshchina AE; Voronkova IA; Ashevskaya VE; Korosteleva PA; Dolzhansky OV
Arkh Patol; 2019; 81(5):11-21. PubMed ID: 31626200
[TBL] [Abstract][Full Text] [Related]
20. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas.
Moretti L; Medeiros LJ; Kunkalla K; Williams MD; Singh RR; Vega F
Mod Pathol; 2012 Feb; 25(2):231-6. PubMed ID: 22037256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]